Alumis Inc (ALMS)

$4.51 -0.10 (-2.17%)
Market Cap 479.74M
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 352,900
Avg Vol 614,114
Day's Range N/A - N/A
Shares Out 104.06M
Stochastic %K 26%
Beta -1.47
Analysts Strong Sell
Price Target $19.00

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
24oldmillclear
24oldmillclear Oct. 15 at 1:15 PM
$ALMS
0 · Reply
Winning_calls
Winning_calls Oct. 13 at 12:31 PM
$ALMS 🫡join the winning team
0 · Reply
Winning_calls
Winning_calls Oct. 13 at 3:46 AM
$ALMS pick me up @ $4.40
0 · Reply
10xby3
10xby3 Oct. 8 at 11:52 AM
$ALMS here we go! 200 day MA watch today and then $6 plus
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Oct. 7 at 9:05 PM
$ALMS 20/50 ma breakout with volume - Insider action $TMC running on volume . Canada primer visited today. ca stocks such as $POET pumping as well Expecting continuation run into the am
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 7 at 5:32 PM
$ALMS just popped 3% higher to 9% (~1Mv) moments ago, 10/17 options, follow for more volatility.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Oct. 4 at 11:45 PM
$ALMS reviewed their data. Very high likelihood of success. I will buy a shit ton if it dips. I expect this to be trading in the 20s once trial data is announced. ****nfa**** Good luck all.
0 · Reply
TalkMarkets
TalkMarkets Sep. 29 at 10:05 PM
Bargain Hunters’ Delight: Four Stocks Trading Below Cash Per Share With Minimal Debt $GDOT $ARVN $KROS $ALMS https://talkmarkets.com/content/stocks--equities/bargain-hunters-delight-four-stocks-trading-below-cash-per-share-with-minimal-debt?post=525519
0 · Reply
Jhgfyij
Jhgfyij Sep. 29 at 9:11 PM
$ALMS
0 · Reply
24oldmillclear
24oldmillclear Sep. 29 at 1:55 AM
$ALMS
0 · Reply
Latest News on ALMS
Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Sep 17, 2025, 4:53 AM EDT - 5 weeks ago

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 2 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 2 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 3 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 3 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 5 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 5 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 5 months ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 5 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 5 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 6 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 6 months ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 6 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 7 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 7 months ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 7 months ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 7 months ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 8 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 8 months ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 8 months ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 8 months ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 8 months ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 8 months ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 9 months ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 9 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 9 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 9 months ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Oct 17, 2024, 2:32 PM EDT - 1 year ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 1 year ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 1 year ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 24, 2024, 3:18 PM EDT - 1 year ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

Jul 1, 2024, 11:51 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

AGH INHI LB LINE TBN TWFG WBTN

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Jun 28, 2024, 1:36 PM EDT - 1 year ago

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 1 year ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 1 year ago

Alumis Announces Pricing of Initial Public Offering

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 8:27 AM EDT - 1 year ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 1 year ago

Alumis eyes $300 million in proceeds in IPO

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

Jun 11, 2024, 12:25 PM EDT - 1 year ago

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

24oldmillclear
24oldmillclear Oct. 15 at 1:15 PM
$ALMS
0 · Reply
Winning_calls
Winning_calls Oct. 13 at 12:31 PM
$ALMS 🫡join the winning team
0 · Reply
Winning_calls
Winning_calls Oct. 13 at 3:46 AM
$ALMS pick me up @ $4.40
0 · Reply
10xby3
10xby3 Oct. 8 at 11:52 AM
$ALMS here we go! 200 day MA watch today and then $6 plus
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Oct. 7 at 9:05 PM
$ALMS 20/50 ma breakout with volume - Insider action $TMC running on volume . Canada primer visited today. ca stocks such as $POET pumping as well Expecting continuation run into the am
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 7 at 5:32 PM
$ALMS just popped 3% higher to 9% (~1Mv) moments ago, 10/17 options, follow for more volatility.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Oct. 4 at 11:45 PM
$ALMS reviewed their data. Very high likelihood of success. I will buy a shit ton if it dips. I expect this to be trading in the 20s once trial data is announced. ****nfa**** Good luck all.
0 · Reply
TalkMarkets
TalkMarkets Sep. 29 at 10:05 PM
Bargain Hunters’ Delight: Four Stocks Trading Below Cash Per Share With Minimal Debt $GDOT $ARVN $KROS $ALMS https://talkmarkets.com/content/stocks--equities/bargain-hunters-delight-four-stocks-trading-below-cash-per-share-with-minimal-debt?post=525519
0 · Reply
Jhgfyij
Jhgfyij Sep. 29 at 9:11 PM
$ALMS
0 · Reply
24oldmillclear
24oldmillclear Sep. 29 at 1:55 AM
$ALMS
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Sep. 29 at 12:21 AM
$ALMS insiders buying. 🔥🔥🔥🚀🚀🚀
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Sep. 24 at 5:03 PM
Liked the move $NKTR and $QURE made. $ALMS I really like! Low float, microcap with a high ocane pipeline that can move the needle in a hurry. Due for psoriasis readout in q1 2026. If early data is positive it can be announced a few months sooner which will cause a monster move. Don't say I didn't tell ya! ***Not financial advice***
1 · Reply
10xby3
10xby3 Sep. 19 at 2:13 AM
$ALMS $ 5er then $6 lets go!
0 · Reply
777Dog
777Dog Sep. 9 at 2:26 PM
$ALMS picked up a few more at 4.14…good luck everybody…
2 · Reply
777Dog
777Dog Sep. 9 at 2:18 PM
$ALMS below cash, first and best in $100+ billion market…let’s see how far down the tutes take it while they accumulate No bad news, steady progress…still buying as we wait…
0 · Reply
JarvisFlow
JarvisFlow Sep. 9 at 10:00 AM
Oppenheimer has adjusted their stance on Alumis ( $ALMS ), setting the rating to Outperform with a target price of 32 → 26.
0 · Reply
777Dog
777Dog Sep. 4 at 2:47 AM
$ALMS listened to presentation. Honestly could not hear much due to audio troubles. They have several very positive studies awaiting completion. Confirmed that phase3 going as predicted by phase 2. They are awaiting results to decide on best allocation of $$$ Several hints at partner likely for launches. CEO is all business and very smart. $20 target is real…will continue to buy dips as it climbs with tutes accumulating.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 11:42 AM
$ALMS Great piece that accurately captures ALMS's current position. So if you want to refresh your understanding of ALMS or learn about ALMS for the first time, this is essential reading. https://beyondspx.com/quote/ALMS/alumis-a-transformed-pipeline-and-strengthened-balance-sheet-post-merger-alms#analysis
0 · Reply
777Dog
777Dog Sep. 3 at 2:47 AM
$ALMS Updates please...$20 Cantor Global Healthcare Conference 2025 in New York, NY on September 3 at 9:45 am ET (fireside chat); Wells Fargo 2025 Healthcare Conference in Boston, MA on September 5 at 9:30 am ET (fireside chat); Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on September 8 at 4:50 pm ET (fireside chat); H.C. Wainwright 27th Annual Global Investment Conference in New York, NY on September 9 at 10:30 am ET (presentation); Baird 2025 Global Healthcare Conference in New York, NY on September 10 at 2:35 pm ET (presentation); and Stifel 2025 Virtual Immunology & Inflammation Forum on September 16 at 12:30 pm ET (virtual presentation)
0 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Aug. 31 at 9:06 PM
$ALMS Super bullish🚀🚀🚀🚀
0 · Reply
777Dog
777Dog Aug. 27 at 1:59 PM
$ALMS For any possible newbies...the chart is painted...tutes loading...
0 · Reply
777Dog
777Dog Aug. 27 at 1:48 PM
$ALMS Great stock to watch...tutes loading while we wait...no reason to think phase 3 will fail, and company run by competent CEO who knows how to get acquired by big Pharma. Flush with cash... Will continue to buy the dips and enjoy the ride to 20 bucks...target is real... good luck everybody...sleeper...
0 · Reply